Alembic Pharma gets USFDA tentative nod for Binimetinib tablets

Alembic Pharma gets USFDA tentative nod for Binimetinib tablets — Alembic Pharmaceuticals has received tentative approval from the USFDA for its Binimetinib Tablets, 45 mg. The drug is a generic version of Novartis’ Mektovi tablets, used for treating melanoma. Tentative approval means the product can launch upon patent expiry or final regulatory clearance. This positions Alembic to enter the US market early and gain revenue momentum.

📊 STOCKS: APLLTD | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA